Sumitomo Pharma’s Xenleta Approved in China for Community-Acquired Pneumonia Treatment
Japan-based Sumitomo Pharma Co., Ltd announced that it has received market approval in China for...
Sumitomo Pharma
Sumitomo Pharma Expands Collaboration with Shanghai Pharmaceuticals for Prescription Drug Co-Marketing
Japan-based Sumitomo Pharma Co., Ltd (TYO: 4506) has announced an expanded Contract Sales Organization (CSO)...
Eslicarbazepine Makes First Appearance in China at Sichuan University’s West China Lecheng Hospital
Eslicarbazepine, a voltage-gated sodium channel blocker, co-developed by Bial-Portela, Eisai, and Sumitomo Pharma, was first...
Sumitomo Pharma’s China CEO Highlights Strategic Importance of Local Market
Yoshitaka Koketsu, CEO of Sumitomo Pharma (TYO: 4506) (China) Co., Ltd, the Chinese subsidiary of...
Health Canada Approves Pfizer and Sumitomo Pharma’s Myfembree for Endometriosis Pain Management
Health Canada has granted regulatory approval to Pfizer (NYSE: PFE) and Sumitomo Pharma (TYO: 4506)...
Sumitomo Pharma and Otsuka’s Ulotaront Fails to Meet Primary Endpoint in Schizophrenia Trials
Japan-based Sumitomo Pharma Co., Ltd (TYO: 4506) and Otsuka Pharmaceutical Co., Ltd (FRA: OS1) have...
Sumitomo Pharma to Invest $30 Million in China for New Product Development
Japan-based Sumitomo Pharma (TYO: 4506), through its China unit, is planning a significant investment of...
Sumitomo Pharma Secures Rights to Vibegron for Asian Markets
Japan-based Sumitomo Pharma Co., Ltd has signed a sub-license deal with compatriot firm Kyorin Pharmaceutical...
Sumitomo Dainippon Partners with Profex to Promote Antipsychotics in China
Japan-based Sumitomo Dainippon Pharma Co., Ltd has announced a partnership with Profex, a trade company...